Studies with an Orally Bioavailable {alpha}V Integrin Antagonist in Animal Models of Ocular Vasculopathy: Retinal Neovascularization in Mice and Retinal Vascular Permeability in Diabetic Rats.

Studies with an Orally Bioavailable {alpha}V Integrin Antagonist in Animal Models of Ocular Vasculopathy: Retinal Neovascularization in Mice and Retinal Vascular Permeability in Diabetic Rats. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Studies with an Orally Bioavailable {alpha}V Integrin Antagonist in Animal Models of Ocular Vasculopathy: Retinal Neovascularization in Mice and Retinal Vascular Permeability in Diabetic Rats. Abstract Text:

Rosemary J Santulli,William A Kinney,Shyamali Ghosh,Bart L Decorte,Li Liu,Robert W A Tuman,Zhao Zhou,Norman Huebert,Sven E Bursell,Alan C Clermont,Maria B Grant,Lynn C Shaw,Shaker A Mousa,Robert A Galemmo,Dana L Johnson,Bruce E Maryanoff,Bruce P Damiano,

The alpha(V) integrins are key receptors involved in mediating cell migration and angiogenesis. In age-related macular degeneration (AMD) and diabetic retinopathy, angiogenesis plays a critical role in the loss of vision. These ocular vasculopathies might be treatable with a suitable alpha(V) antagonist, and an oral drug would offer a distinct advantage over current therapies. (3,S,beta,S)-1,2,3,4-Tetrahydro-beta-[[1-[1-oxo-3-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)propyl]-4-piperidinyl]methyl]-3-quinolinepropanoic acid (JNJ-26076713) is a potent, orally bioavailable, nonpeptide alpha(V) antagonist derived from the arginine-glycine-asparagine binding motif in the matrix protein ligands (e.g., vitronectin). This compound inhibits alpha(V)beta(3) and alpha(V)beta(5) binding to vitronectin in the low nanomolar range, it has excellent selectivity over integrins alpha(IIb)beta(3) and alpha(5)beta(1), and it prevents adhesion to human, rat, and mouse endothelial cells. JNJ-26076713 blocks cell migration induced by vascular endothelial growth factor, fibroblast growth factor (FGF), and serum, and angiogenesis induced by FGF in the chick chorioallantoic membrane model. JNJ-26076713 is the first alpha(V) antagonist reported to inhibit retinal neovascularization in an oxygen-induced model of retinopathy of prematurity after oral administration. In diabetic rats, orally administered JNJ-26076713 markedly inhibits retinal vascular permeability, a key early event in diabetic macular edema and AMD. Given this profile, JNJ-26076713 represents a potential therapeutic candidate for the treatment of age-related macular degeneration, macular edema, and proliferative diabetic retinopathy.

Studies with an Orally Bioavailable {alpha}V Integrin Antagonist in Animal Models of Ocular Vasculopathy: Retinal Neovascularization in Mice and Retinal Vascular Permeability in Diabetic Rats. Publishing Authors By Initials

RJ Santulli,WA Kinney,S Ghosh,BL Decorte,L Liu,RW Tuman,Z Zhou,N Huebert,SE Bursell,AC Clermont,MB Grant,LC Shaw,SA Mousa,RA Galemmo,DL Johnson,BE Maryanoff,BP Damiano,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Studies with an Orally Bioavailable {alpha}V Integrin Antagonist in Animal Models of Ocular Vasculopathy: Retinal Neovascularization in Mice and Retinal Vascular Permeability in Diabetic Rats. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: The Journal of pharmacology and experimental thera

VOLUME: 324

Page Numbers: 894-901

Journal Abbreviation: J. Pharmacol. Exp. Ther.

ISSN: 1521-0103

DAY: 14

MONTH: 12

YEAR: 2007

Studies with an Orally Bioavailable {alpha}V Integrin Antagonist in Animal Models of Ocular Vasculopathy: Retinal Neovascularization in Mice and Retinal Vascular Permeability in Diabetic Rats. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 376362

Studies with an Orally Bioavailable {alpha}V Integrin Antagonist in Animal Models of Ocular Vasculopathy: Retinal Neovascularization in Mice and Retinal Vascular Permeability in Diabetic Rats. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Studies with an Orally Bioavailable {alpha}V Integrin Antagonist in Animal Models of Ocular Vasculopathy: Retinal Neovascularization in Mice and Retinal Vascular Permeability in Diabetic Rats. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Studies with an Orally Bioavailable {alpha}V Integrin Antagonist in Animal Models of Ocular Vasculopathy: Retinal Neovascularization in Mice and Retinal Vascular Permeability in Diabetic Rats.

AFFILIATION: Johnson & Johnson Pharmaceutical Research & Development, Welsh and McKean Rds., Spring House, PA 19477-0776. rsantull@prdus.jnj.com.

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: J Pharmacol Exp Ther

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Studies with an Orally Bioavailable {alpha}V Integrin Antagonist in Animal Models of Ocular Vasculopathy: Retinal Neovascularization in Mice and Retinal Vascular Permeability in Diabetic Rats Related Publications

• A feasible and reliable muscle fatigue assessment protocol for individuals with cerebral palsy.
• A novel bioengineered small-caliber vascular graft incorporating heparin and sirolimus: Excellent 6-month patency.
• Aortic valve replacement in octogenarians: risk factors for early and late mortality.
• Atrial fibrillation propagates through gaps in ablation lines: Implications for ablative treatment of atrial fibrillation.
• Curing atrial fibrillation: Two decades of progress.
• Four-year cost-utility analyses of sealed and nonsealed first permanent molars in Iowa Medicaid-enrolled children.
• Isolating the entire posterior left atrium improves surgical outcomes after the Cox maze procedure.
• MR imaging of the pituitary stalk: size, shape, and enhancement pattern.
• Mechanisms of human atrial fibrillation: Lessons learned from 20 years of atrial fibrillation surgery.
• Mer receptor tyrosine kinase signaling participates in platelet function.
• Onset of symptomatic effect of mometasone furoate nasal spray in the treatment of nasal polyposis.
• Partial development of the corpus callosum.
• Patient-specific surgical strategy for atrial fibrillation: promises and challenges.
• Pharmacodynamics and stability of subcutaneously infused glucagon in a type 1 diabetic Swine model in vivo.
• Pharmacological characterization of RWJ-676070, a dual vasopressin V(1A)/V(2) receptor antagonist.
• Question 9: theoretical and artificial construction of the living: redefining the approach from an autopoietic point of view.
• Re: ureteral stenting and urinary stone management: a systematic review g. Haleblian, k. Kijvikai, j. De la rosette and g. Preminger j urol 2008; 179: 424-430.
• Recurrent mitral regurgitation and risk factors for early and late mortality after mitral valve repair for functional ischemic mitral regurgitation.
• Studies with an Orally Bioavailable {alpha}V Integrin Antagonist in Animal Models of Ocular Vasculopathy: Retinal Neovascularization in Mice and Retinal Vascular Permeability in Diabetic Rats.
• Surgery for atrial fibrillation: Current state-of-the-art.
• Surgical ablation devices for atrial fibrillation.
• Surgical treatment of atrial fibrillation with bipolar radiofrequency ablation: mid-term results in one hundred consecutive patients.
• The Endothelial Glycocalyx is Hydrodynamically Relevant in Arterioles throughout the Cardiac Cycle.
• The hydrodynamically relevant endothelial cell glycocalyx observed in vivo is absent in vitro.
• The structure and function of the endothelial glycocalyx layer.
• What is the best way to surgically eliminate the left atrial appendage?